Page 12 - Today Biogen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biogen Inc : Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data

(0) TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current thrombolytics are limited in use due in part to increased risks of bleeding Phase 2a study demonstrated positive impacts on blood vessel reopening and patient functional recovery with no incidence of symptomatic intracranial hemorrhage Biogen to make a one-time payment of $18 million and may pay potential milestone payments and royalties to TMS Co., Ltd. CAMBRIDGE, Mass. and FUCHU-SHI, Tokyo, May 12, 2021Inc (Nasdaq: BIIB) and TMS Co., Ltd. announced today that Biogen exercised its option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS. Biogen s decision to acquire TMS-007 was based on positive data from a Phase 2a study. The study met its primary safety objective with no incidence of symptomatic intracranial hemorrhage (sICH) and demonstrated positive imp

United kingdomUnited statesFuchu shiDavid caouetteMike henckeWalter gilbertCharles weissmannHeinz schallerKenneth murrayAlfred sandrock jrCo ltdAmerican heart associationProfessor of the universityInc nasdaqNational institute of health stroke scaleExchange commission

Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders

Search jobs 11-May-2021 Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders Collaboration aims to identify novel AAV capsids with enhanced properties to facilitate the development of new gene therapies for CNS and neuromuscular disorders Capsigen’s screening technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across Biogen’s gene therapy pipeline Capsigen to receive a $15 million upfront payment and is eligible to receive potential research, development and commercial milestone payments Biogen Inc. (Nasdaq: BIIB) and Capsigen Inc. announced today that they have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to deliver transformative gene therapies that address the underlying genetic causes of various CNS and neuromuscular

Heinz schallerWalter gilbertCharles weissmannKenneth murrayJohn bialAlfred sandrock jrHead of researchCapsigen incBiogen incExchange commissionAlfred sandrockChief executiveNobel prizeToday biogenPrivate securities litigation reform actஹெய்ன்ஸ் ஸ்காலர்

Biogen Inc : Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics

Accelerated action on climate, health and equity, including new plastic-free packaging goals for finished goods by 20251Disclosed 2020 global pay equity analysis results2 and launched enhanced four-part

United kingdomUnited statesDavid caouetteMike henckeWalter gilbertCharles weissmannHeinz schallerMichel vounatsosKenneth murrayBiogen foundationExchange commissionTask force on climateTask forceClimate related financial disclosuresStakeholder capitalismChief executive officer

18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimers Disease Published in Peer-Reviewed Journal, Alzheimers Research and Therapy

18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimers Disease Published in Peer-Reviewed Journal, Alzheimers Research and Therapy
pressreleasepoint.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressreleasepoint.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesHaruo naitoWalter gilbertCharles weissmannHeinz schallerMichel vounatsosDavid caouetteJeffrey cummingsMike henckeMichael irizarryKenneth murrayDepartment of brain healthAlzheimer association international conferenceInvestor relations departmentNational institute on

Biogen Inc : Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

Biogen Inc.: Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients (nusinersen) Additional research reinforces the potential of biomarkers and highlights new digital tools that may help guide future treatment approaches and decisions for people with SMA CAMBRIDGE, Mass., April 19, 2021Inc. (Nasdaq: BIIB) today announced new data from the SPINRAZA (nusinersen) clinical development program aimed at optimizing outcomes for people with spinal muscular atrophy (SMA) and advancing understanding of the disease. These data are being presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting, April 17-22.

United kingdomUnited statesCharles weissmannWalter gilbertHeinz schallerAlfred sandrock jrDavid caouetteMike henckeKonectom smartphoneKenneth murrayHead of researchIonis pharmaceuticals incBiogen incExchange commissionAmerican academy of neurologyIonis pharmaceuticals